Varian Medical Systems (VAR) Tops Q3 EPS by 9c, Slight Miss on Revenues; 'Q4 Revenue Growth Expected Flat to Down Slightly'

Varian Medical Systems (NYSE: VAR) reported Q3 EPS of $1.04, $0.09 better than the analyst estimate of $0.95. Revenue for the quarter came in at $662.4 million versus the consensus estimate of $663.91 million.

Outlook

Fourth quarter revenue growth is now expected to be flat to down slightly. For Q217 to Q417, revenue growth is expected to be between 2 and 3 percent, including the impact of proton revenues. Non-GAAP diluted earnings per share from continuing operations are expected to be in the range of $1.15 to $1.23 for the fourth quarter and between $3.08 and $3.16 for Q217 to Q417, including the earnings contribution of the proton business.

GUIDANCE:

Varian Medical Systems sees Q4 2017 EPS of $1.15-$1.23, versus the consensus of $1.19.

For earnings history and earnings-related data on Varian Medical Systems (VAR) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Assembly Biosciences (ASMB) Tops Q2 EPS by 53c
• Innovaro (INV) Misses Q2 EPS by 9c